Novo Integrated Sciences, INC 8-K filings

Novo Integrated Sciences extends the resignation date of its CEO and announces the resignation of a board member.

Novo Integrated Sciences, Inc. (NVOS) is set to be delisted from the Nasdaq Stock Market after failing to meet the minimum bid price requirement, with trading continuing on the OTC Market.

Novo Integrated Sciences announces another extension to the resignation date of CEO Robert Mattacchione to facilitate a smoother transition.

Novo Integrated Sciences, Inc. announces a further extension to the resignation date of CEO Robert Mattacchione to ensure a smooth transition.

Novo Integrated Sciences extends the resignation date of CEO Robert Mattacchione to no later than March 7, 2025, to ensure a smooth transition.

Robert Mattacchione's resignation as CEO of Novo Integrated Sciences has been extended to February 20, 2025, to facilitate a smoother transition.

Novo Integrated Sciences announced its fiscal year 2024 results, showing a 6% increase in revenue but a significant rise in net loss due to increased operating costs and other factors.

Novo Integrated Sciences held its annual meeting, electing three directors, approving a reverse stock split, and ratifying its auditors.

Novo Integrated Sciences has withdrawn a proposal for potential share issuance due to its delisting from the Nasdaq Capital Market, while still proceeding with other key proposals at its upcoming annual meeting.

Novo Integrated Sciences announces the resignation of its CEO, Robert Mattacchione, effective in 90 days, while he will remain as Chairman of the Board and Chairman of a subsidiary.

Novo Integrated Sciences, Inc. has received notice of delisting from the Nasdaq Capital Market due to non-compliance with minimum bid price requirements, with trading expected to move to the OTC Market on November 6, 2024.

Robert Oliva resigned as President of Novo Integrated Sciences, Inc. effective October 25, 2024.

Novo Integrated Sciences' agreement to purchase the Ophir Collection for $60 million has been terminated by the court-appointed receiver.

Novo Integrated Sciences received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and intends to appeal the decision.

Novo Integrated Sciences reported a decrease in revenue and a significant increase in net loss for the third quarter of fiscal year 2024, despite growth in healthcare services revenue.

Novo Integrated Sciences has received notice of the commencement of disbursement for the monetization of a Standby Letter of Credit, with an expected total of $78 million in gross funding proceeds.

Novo Integrated Sciences has amended its agreement with Streeterville Capital, extending the deadline for filing a registration statement for 3.5 million shares to July 3, 2024, and waiving any prior defaults.

Novo Integrated Sciences has extended the employment agreements of CEO Robert Mattacchione and COO Christopher David by one year, continuing their terms until June 18, 2025.

Novo Integrated Sciences has received confirmation of a Standby Letter of Credit from HSBC, a key step in a program expected to yield $78 million in gross funding.

Novo Integrated Sciences has increased its stock repurchase program to $10 million, contingent on the receipt of funds from a pending debt financing and the monetization of a Standby Letter of Credit.

Acenzia, a subsidiary of Novo Integrated Sciences, will participate in a $5.4 million project with Protein Industries Canada to develop new plant-based protein products.

Novo Integrated Sciences has amended its $70 million promissory note with RC Consulting, allowing for potential prepayment with restricted shares if the stock price exceeds $15.

Novo Integrated Sciences has approved a stock repurchase program of up to $5 million and is conducting a strategic review to potentially increase the amount.

Novo Integrated Sciences has received confirmation of a Ready, Willing and Able (RWA) from HSBC for a Standby Letter of Credit (SBLC) expected to provide $78 million in funding.

Novo Integrated Sciences announced a 24% increase in revenue and a 41% decrease in net loss for the second fiscal quarter of 2024, driven primarily by increased product sales.

Novo Integrated Sciences has secured a $6.21 million loan from Streeterville Capital, using a portion of the funds to repay existing debt.

Novo Integrated Sciences converted debt into over 1.3 million shares of common stock for two entities, Mast Hill and FirstFire.

Novo Integrated Sciences has provided an update on its progress regarding the acquisition of the Ophir Collection, a promissory note agreement, and the monetization of a gold-backed bond.

Novo Integrated Sciences obtained a limited waiver from RC Consulting Consortium Group LLC, modifying restrictions on how the company can use proceeds from a $70 million loan.

Novo Integrated Sciences has transferred its $70 million promissory note and related security purchase agreement to a new holder, RC Consulting Consortium Group LLC.